Insulin Resistance Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Insulin
Resistance – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Insulin Resistance – Pipeline Review, H1 2019, provides comprehensive
information on the therapeutics under development for Insulin Resistance
(Metabolic Disorders), complete with analysis by stage of development,
drug target, mechanism of action (MoA), route of administration (RoA)
and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development
history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews
of key players involved in therapeutic development for Insulin
Resistance and features dormant and discontinued projects. The guide
covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase II, Phase I,
Preclinical and Discovery stages are 1, 2, 7 and 1 respectively.
Similarly, the Universities portfolio in Preclinical stages comprises 5
molecules, respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic
  landscape of Insulin Resistance (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Insulin
  Resistance (Metabolic Disorders) by companies and
  universities/research institutes based on information derived from
  company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of
  development ranging from pre-registration till discovery and
  undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline
  products which comprise, product description, descriptive licensing
  and collaboration details, R&D brief, MoA & other developmental
  activities.
• The pipeline guide reviews key companies involved in Insulin
  Resistance (Metabolic Disorders) therapeutics and enlists all their
  major and minor projects.
• The pipeline guide evaluates Insulin Resistance (Metabolic Disorders)
  therapeutics based on mechanism of action (MoA), drug target, route of
  administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued
  pipeline projects.
• The pipeline guide reviews latest news related to pipeline
  therapeutics for Insulin Resistance (Metabolic Disorders)

Reasons to buy:

• Procure strategically important competitor information, analysis, and
  insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio
  and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under
  development for Insulin Resistance (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of
  leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players
  and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding
  Insulin Resistance (Metabolic Disorders) pipeline depth and focus of
  Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by
  identifying prospective partners with the most attractive projects to
  enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects
  and understand from the know-how what drove them from pipeline.

Companies Involved in Therapeutics Development

• BioElectron Technology Corp
• Caelus Health
• F. Hoffmann-La Roche Ltd
• Lixte Biotechnology Holdings Inc
• NorthSea Therapeutics BV
• Pfizer Inc
• Recursion Pharmaceuticals Inc

Insulin Resistance – Drug Profiles

• BioE-206 – Drug Profile
• CDN-1163 – Drug Profile
• CP-001 – Drug Profile
• englerin A – Drug Profile
• FC-98 – Drug Profile
• Fusion Proteins to Target hOGG1 for Insulin Resistance – Drug Profile
• icosabutate – Drug Profile
• LB-100 – Drug Profile
• RG-7992 – Drug Profile
• sildenafil citrate – Drug Profile
• Small Molecule for Atherosclerosis and Insulin Resistance – Drug
  Profile
• Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic
  Disorders – Drug Profile
• Small Molecules for Immunology, Metabolic Disorders and
  Musculoskeletal Disorders – Drug Profile
• Small Molecules for Inherited Insulin Resistance Syndrome – Drug
  Profile
• SYM-401 – Drug Profile
• TM-25659 – Drug Profile

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/mhnzfs/insulin?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs